The Poor Are the Raw Material

Ask who benefits from plasma and you'll get a long list: patients who need immune globulin, hospitals that treat them, and the fractionators who sell it. Ask who pays and the answer is narrower. The cost of the U.S. paid-donation model lands disproportionately on people with low incomes — the donors whose health is spent to supply the world's plasma. Europe looked at this trade and decided it was unethical. The United States decided it was a market.

This page is about that gap: who the centers are built around, what a donation costs someone who can't afford to eat well, and why the rest of the developed world refused to build an industry this way.

The geography of plasma: centers cluster where people need the money

The first thing to understand is where plasma centers choose to open. They are not distributed evenly across a city. They cluster in lower-income neighborhoods — and the reason is straightforward.

• The donor pool is the labor supply. A center needs regular, repeat donors, twice a week. That means a dependable stream of people who can justify the trip on the money it returns. In a high-income neighborhood, $30–70 a visit is not worth two hours of a body's protein. In a low-income one, it is.
• Siting is a business decision, not a health decision. Companies locate near the supply they intend to draw on. Where the supply is cheapest — where the money matters most — is where the centers appear.
• Reporting documents the pattern. Investigative coverage of the industry has long described it in these terms: companies buying plasma from Americans who need the income, with centers concentrated in the communities least able to refuse.

The U.S. plays an outsized role here precisely because of this paid model. It collects roughly 70% of the world's plasma supply — a share that international reporting keeps flagging, most recently in coverage of how dependent other countries have become on American donors. The countries that use the plasma are, to a large degree, not the ones whose poor people supply it.

The poverty premium: the same donation costs the poor more

Here's the part that rarely gets said out loud. To the industry, a donation is a donation — a fixed volume of plasma, worth the same at the top of the chain no matter whose arm it came from. But to the donor, the cost of that donation is not fixed. It depends on what you ate.

Every donation removes 50–80 grams of protein, on top of the immunoglobulins (IgG, which takes weeks to rebuild, with a roughly 21-day half-life) and iron stored as ferritin. Your body has to replace all of that from your diet. That's where your income shows up.

So the industry's safety claims rest on an assumption it doesn't provide for: that the donor can eat well enough to keep up. The two-per-week maximum that looks fine in a healthy, well-fed sample is not fine for a food-insecure donor who is donating precisely because they need the money. The same milliliter of plasma costs a poor donor their muscle and their immune reserve — the "poverty premium" built into every visit. (For how that plays out in the clinic, see how centers work.)

Europe said no: the ethical line the U.S. wouldn't draw

The clearest proof that this is a choice, not an inevitability, is that the rest of the developed world refused to make it. Europe banned paid plasma donation.

• The principle is voluntary, non-remunerated donation. Across Europe, donating blood and plasma is unpaid, and the governing bodies of the Council of Europe explicitly prohibit financial gain from donation.
• The reasoning is ethical, not medical. The concern isn't that paid donation is unsafe — it's that paying for body parts exploits the vulnerable. When you pay for plasma, the people who donate are disproportionately the ones who can't afford to decline.
• The U.S. is the outlier. It is the only major developed country that compensates plasma donors at scale — which is exactly why it supplies most of the world's plasma.

The United States has to work around the obvious problem that it's doing something other countries consider a human-rights violation. It does this with language: the FDA classifies the payment as compensation, not purchase. Under 21 CFR Part 640, the rules governing source plasma treat the donor as compensated rather than as selling a product. That framing keeps the practice legal and even sounds benign — you're not buying a body part, you're paying someone for their time and inconvenience. But the money functions exactly like a price, and it's the price that decides who donates.

The European stance is an explicit acknowledgment that this is a moral question. The United States decided it was a supply-chain question instead.

The moral math: what a $50 buys, and what it costs

Strip the industry's language away and you're left with a transaction. On one side of the scale:

• What the donor gets: about $30–70 per visit, roughly $20–40 an hour over a ~90-minute visit. For a low-income donor, that's real money — often the difference between making rent and not.
• What the donor gives: 50–80 g of protein that takes days to replace, IgG that takes weeks, and iron that's hard to replenish on a limited food budget.

And on the other side of the scale, what the industry does with it: the same plasma becomes $1,000+ immune globulin infusions and a whole $50 billion world supply. (Follow that money in the money trail.)

That's the genuine trade. It isn't that donors are fools — it's that the system prices a hard choice so that the people least able to say no are the ones who carry it. Europe decided the vulnerable shouldn't be put in that position. The U.S. decided to reward the people who were.